Skin Elements (ASX: SKN) pioneering modern natural biotechnology with SE FormulaTM - Kalkine Media

Highlights

• Formulation company Skin Elements is now stepping up from innovation to commercialisation.
• The Eco Nurture crop sample testing returned improved stress tolerance, wellness and natural resilience levels during investigations and prototype formulation during the year.
• SKN is engaged in expanding the SuprCuvr product range, with the development of SuprCuvr biodegradable and compostable wipes.
• In FY23, the company raised capital through a placement and entitlement issue.

Listed on the Australian Securities Exchange, Skin Elements Limited (ASX: SKN) is a formulation company that is now stepping up from innovation to commercialisation.

The company has built its proprietary skincare formulas, like the natural disinfectant hygiene cleaner SuprCuvr and Eco Nurture formulas, the Soleo Organics natural sunscreen, the PapayaActivs therapeutic skincare, and the Elizabeth Jane Natural Cosmetics following a thorough research and development of its proprietary SE Formula^TM Biotechnology. Now, Skin Elements has its focus on further development as well as commercialisation of its natural anti-microbial technology.

In this article, we will talk about some crucial developments that the company undertook during the twelve-month period ended 30 June 2023.

Eco Nurture Plant Bio Stimulant

A sustainable, horticultural-specific plant-based bio stimulant product, Eco Nurture serves as an effective alternative to chemical-based bactericides and fungicides currently used in crop protection globally. The product paves way for the company in the massive agriscience market.

The Eco Nurture crop sample testing returned improved stress tolerance, wellness and natural resilience levels in a number of fruit crops during the research phase 1 investigations and prototype formulation during the year. The results received so far reinforces the ability of Eco Nurture as a replacement to harmful chemicals, including copper sulphates, used in crop production. The company is now planning to undertake development phase 2 testing.

SuprCuvr

A TGA registered hospital-grade disinfectant, SuprCuvr has a 7-log reduction (99.99999%) effectiveness against bacteria and viruses, as per independent laboratory tests. The chemical-free disinfectant SuprCuvr has been made from a 100% plant-based formula. The product presents a major market opportunity in large-scale settings where disinfectants are essential.

Presently, SKN is engaged in expanding the SuprCuvr product range, with the development of SuprCuvr biodegradable and compostable wipes.

The company is working in collaboration with Pacific Health Care Pty Ltd to upgrade the formula potency, competitive pricing structure and packaging presentation, after understanding the response of the market.

Image source: Company website

Cosmetic Skincare – Soleo Organics

Soléo Organics is a sun protection product considered as one of the world’s best sun protection formulas. The company is involved in initiating Soléo Organics development phase 3, after completion of its development phase 2. SKN has partnered with a health and wellbeing retail chain based in the United Kingdom, and is planning to produce white label ranges on a large scale.

Image source: Company website

Cosmetic Skincare – PapayaActivs

PapayaActivs is currently in development phase 2 with improvements in the formulations and expansion of the product range. PapayaActivs combines a high concentration of natural pawpaw extract with other active natural ingredients to help relieve the symptoms of skin conditions, like psoriasis, eczema, assist in healing of minor burns and wounds, and relieve mild muscle, joint and arthritic pain. PapayaActivs is listed on the TGA’s Australian Register of Therapeutic Goods.

Image source: Company website

Research and development (R&D) tax incentive grant income

The company received a record R&D tax incentive grant income of AU$1.13 million for the R&D (research and development) expenditure invested in the 2023 financial year on its natural SE Formula Biotechnology.

SKN received advance funding of AU$538,000 of this R&D tax incentives under a facility with Radium Capital in FY23, while the remaining amount was received post 30 June 2023.

Placement raises AU$750,000

Last year in November, SKN raised AU$750,000 through a placement to sophisticated investors. Under the placement, total 30,000,000 ordinary fully paid shares were issued at AU$0.025 each with one attaching option exercisable at AU$0.05 on or before 31 October 2025 for each new share.

SKN shares traded at AU$0.005 on 13 October 2023.